Capsular K-antigen-PLGA Nano conjugated Vaccine against Klebsiella pneumoniea pneumoniae K2O1 Infection

Klebsiella pneumoniae is the most common pathogenic bacterium in the genus Klebsiella (1). The aim of this study was to use Polylactic-co-glycolic acid (PLGA) nanoparticles in vaccine design of the capsule antigen of Klebsiella pneumoniae K2O1.The capsular antigen was loaded into the polylactic-co-glycolic acid (PLGA) nanoparticles by W/O /W method (5). FT-IR and AFM were used to confirm capsule antigen loading and morphology of the nanoparticles, respectively (6,7). The fever after the vaccination was tested by limolus amoebocyte lysate assay (LAL test)(8). The investigation of the serum of mice by ELISA. Histopathological examination of lung, liver and spleen organs of vaccinated mice in four groups containing five female BALB/C mice (6-7 week-old) was studied after challenge with Klebsiella pneumoniae. Mice vaccinated with nanoparticles containing Klebsiella pneumoniae capsular antigen showed that the proposed vaccine has a high potential for long-term and stable protection against pure Klebsiella pneumoniae capsule antigen, activates (T Helper) lymphocytes T, and stimulates memory by stimulating T cells. Indicating the effectiveness of the vaccine, the results revealed that the vaccine could be recommended for animal studies with more samples or phase one clinical trial studies.